StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) income statement

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3034% above fair value
$36.48+0.02 (+0.05%)

Close on Nov 16, 2026Market cap $1.45BP/E 104.2Yield –

Pacira BioSciences, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
79.2%
Operating margin
2.7%
Net margin
2.0%
Return on equity, FY2025
1.0%

Financial strength

Current ratio
5.04
Debt to equity
0.54
Debt to assets
29.2%
Cash to current liabilities
168.7%

Valuation

P/E ratio
104.2
Price to sales
1.95
Price to book
2.16
Dividend yield
–

See a number that looks wrong?